PDCD1LG2 and breast carcinoma: Therefore, miR-93-5p, as a circulating miRNA with multiple targets of immune checkpoints (including PD-L1, PD-L2, and B7-H6), has been considered to possess the potential in breast cancer immunotherapy, by a possible mechanism of reducing the expression of PD-L1, PD-L2, and B7-H6.